Class B GPCRs, such as the glucagon-like peptide-1 receptor (GLP-1R), play crucial roles in the control of glucose and energy metabolism and are key investigational targets for the treatment of several metabolic disorders including insulin resistance, obesity, and type 2 diabetes (T2D) [18]. This evidence concerns the gene GLP1R and metabolic disease.